
AstraZeneca Makes $5.3B AI Bet With China’s CSPC for Chronic Disease Pills
AstraZeneca put down $110 million upfront to partner with China’s CSPC Pharmaceutical, aiming to leverage AI to develop novel oral therapies for a wide variety of chronic diseases, in a deal announced Friday. Aside from its initial commitment, AstraZeneca …